Tvardi Therapeutics (TVRD) Competitors

$4.00 +0.04 (+1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$4.01 +0.01 (+0.37%)

As of 04:33 PM Eastern

TVRD vs. MENS, HURA, SPRO, CRDL, and ASRT

Should you buy Tvardi Therapeutics stock or one of its competitors? MarketBeat compares Tvardi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tvardi Therapeutics include Jyong Biotech (MENS), TuHURA Biosciences (HURA), Spero Therapeutics (SPRO), Cardiol Therapeutics (CRDL), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry.

How does Tvardi Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Jyong Biotech's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has a consensus price target of $55.50, indicating a potential upside of 1,287.50%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Jyong Biotech and Jyong Biotech both had 4 articles in the media. Jyong Biotech's average media sentiment score of 1.63 beat Tvardi Therapeutics' score of -0.16 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jyong Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

44.7% of Tvardi Therapeutics shares are held by institutional investors. 3.1% of Tvardi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Jyong Biotech has higher earnings, but lower revenue than Tvardi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	N/A	N/A	N/A
Tvardi Therapeutics	$7.14M	5.25	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats Jyong Biotech on 7 of the 10 factors compared between the two stocks.

How does Tvardi Therapeutics compare to TuHURA Biosciences?

Tvardi Therapeutics (NASDAQ:TVRD) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Tvardi Therapeutics has higher revenue and earnings than TuHURA Biosciences. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	5.25	-$18.21M	-$3.10	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.63	N/A

Tvardi Therapeutics' return on equity of -64.17% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
TuHURA Biosciences	N/A	-182.40%	-117.49%

In the previous week, TuHURA Biosciences had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for TuHURA Biosciences and 4 mentions for Tvardi Therapeutics. TuHURA Biosciences' average media sentiment score of 0.65 beat Tvardi Therapeutics' score of -0.16 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tvardi Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Tvardi Therapeutics currently has a consensus price target of $55.50, indicating a potential upside of 1,287.50%. TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 289.61%. Given Tvardi Therapeutics' higher possible upside, research analysts clearly believe Tvardi Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 3.1% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Tvardi Therapeutics beats TuHURA Biosciences on 10 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Spero Therapeutics has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	2.42	$8.57M	$0.12	23.25
Tvardi Therapeutics	$7.14M	5.25	-$18.21M	-$3.10	N/A

Tvardi Therapeutics has a consensus target price of $55.50, indicating a potential upside of 1,287.50%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Spero Therapeutics has a net margin of 24.90% compared to Tvardi Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 38.62% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	38.62%	24.68%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

In the previous week, Spero Therapeutics and Spero Therapeutics both had 4 articles in the media. Spero Therapeutics' average media sentiment score of 1.22 beat Tvardi Therapeutics' score of -0.16 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spero Therapeutics beats Tvardi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Tvardi Therapeutics' return on equity of -64.17% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Cardiol Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 543.94%. Tvardi Therapeutics has a consensus price target of $55.50, suggesting a potential upside of 1,287.50%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Cardiol Therapeutics had 10 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 14 mentions for Cardiol Therapeutics and 4 mentions for Tvardi Therapeutics. Cardiol Therapeutics' average media sentiment score of 0.19 beat Tvardi Therapeutics' score of -0.16 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardiol Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tvardi Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Tvardi Therapeutics	$7.14M	5.25	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Assertio?

Assertio (NASDAQ:ASRT) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Tvardi Therapeutics has a net margin of 0.00% compared to Assertio's net margin of -34.94%. Assertio's return on equity of -38.72% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assertio	-34.94%	-38.72%	-13.32%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Assertio currently has a consensus price target of $22.65, suggesting a potential downside of 2.87%. Tvardi Therapeutics has a consensus price target of $55.50, suggesting a potential upside of 1,287.50%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Assertio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assertio	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Assertio had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 7 mentions for Assertio and 4 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of -0.16 beat Assertio's score of -0.20 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Assertio	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Assertio has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

49.0% of Assertio shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 5.7% of Assertio shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tvardi Therapeutics has lower revenue, but higher earnings than Assertio. Assertio is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assertio	$118.71M	1.27	-$30.38M	-$5.69	N/A
Tvardi Therapeutics	$7.14M	5.25	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats Assertio on 10 of the 17 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.52M	$3.32B	$6.22B	$12.27B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-1.29	18.21	20.16	25.24
Price / Sales	5.25	283.14	541.97	73.15
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	2.58	6.72	9.81	6.90
Net Income	-$18.21M	$24.16M	$3.56B	$333.88M
7 Day Performance	-4.31%	3.87%	0.29%	0.02%
1 Month Performance	15.27%	-3.02%	-0.99%	1.75%
1 Year Performance	N/A	68.84%	36.15%	32.64%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	1.9914 of 5 stars	$4.00 +1.0%	$55.50 +1,287.5%	N/A	$37.52M	$7.14M	N/A	80	Earnings Report Gap Down
MENS Jyong Biotech	N/A	$2.05 flat	N/A	N/A	$155.86M	N/A	N/A	31	News Coverage Positive News Earnings Report
HURA TuHURA Biosciences	2.6629 of 5 stars	$2.38 -0.8%	$9.00 +278.2%	-35.5%	$151.57M	N/A	N/A	N/A	Earnings Report
SPRO Spero Therapeutics	1.4812 of 5 stars	$2.56 +2.0%	N/A	+324.6%	$148.23M	$66.80M	21.34	150	Earnings Report
CRDL Cardiol Therapeutics	2.2554 of 5 stars	$1.32 +1.5%	$8.50 +543.9%	+23.4%	$147.60M	N/A	N/A	20	News Coverage Earnings Report Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. MENS, HURA, SPRO, CRDL, and ASRT

How does Tvardi Therapeutics compare to Jyong Biotech?

Summary

How does Tvardi Therapeutics compare to TuHURA Biosciences?

Summary

How does Tvardi Therapeutics compare to Spero Therapeutics?

Summary

How does Tvardi Therapeutics compare to Cardiol Therapeutics?

Summary

How does Tvardi Therapeutics compare to Assertio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. MENS, HURA, SPRO, CRDL, and ASRT

How does Tvardi Therapeutics compare to Jyong Biotech?

Is MENS or TVRD more profitable?

Do analysts prefer MENS or TVRD?

Does the media prefer MENS or TVRD?

Do insiders & institutionals believe in MENS or TVRD?

Which has better valuation and earnings, MENS or TVRD?

Summary

How does Tvardi Therapeutics compare to TuHURA Biosciences?

Which has stronger valuation and earnings, TVRD or HURA?

Is TVRD or HURA more profitable?

Does the media prefer TVRD or HURA?

Which has more risk & volatility, TVRD or HURA?

Do analysts rate TVRD or HURA?

Do institutionals & insiders believe in TVRD or HURA?

Summary

How does Tvardi Therapeutics compare to Spero Therapeutics?

Which has stronger valuation & earnings, SPRO or TVRD?

Do analysts recommend SPRO or TVRD?

Is SPRO or TVRD more profitable?

Does the media refer more to SPRO or TVRD?

Which has more volatility and risk, SPRO or TVRD?

Do institutionals and insiders have more ownership in SPRO or TVRD?

Summary

How does Tvardi Therapeutics compare to Cardiol Therapeutics?

Is CRDL or TVRD more profitable?

Do analysts rate CRDL or TVRD?

Does the media favor CRDL or TVRD?

Which has more risk & volatility, CRDL or TVRD?

Do insiders and institutionals hold more shares of CRDL or TVRD?

Which has higher valuation & earnings, CRDL or TVRD?

Summary

How does Tvardi Therapeutics compare to Assertio?

Is ASRT or TVRD more profitable?

Do analysts recommend ASRT or TVRD?

Does the media favor ASRT or TVRD?

Which has more volatility and risk, ASRT or TVRD?

Do institutionals and insiders hold more shares of ASRT or TVRD?

Which has stronger valuation and earnings, ASRT or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools